Imaging apoptosis

Molecular Imaging in Oncology

Volumn , Issue , 2008, Pages 493-502

  Belhocine, T Z ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891592567     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (93)

1. Kerr JFR, Winterford CM, Harmon BV. Apoptosis-its significance in cancer and cancer therapy. Cancer 1994; 73(2):2013-2026.
2. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17(9):2941-2953.
3. Hainault P, Hollstein M. p53 and human cancer: the first ten thousands mutations. Adv Cancer Res 2000; 77:81-137.
4. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995; 7:541-546.
5. Los M, Burek CJ, Stroh C, et al. Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov Today 2003; 8:67-77.
6. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256:42-49.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
8. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist 2002; 7:401-107.
9. Biomarkers and surrogate endpoints: advancing clinical research and applications. Sponsored by the National Institutes of Health and Food and Drug Administration at Natcher Conference Center, Bethesda, MD, April 15-16, 1999.
10. Zerhouni E. The NIH Roadmap. Science 2003; 302:63-72. Available at: http://nihroadmap.nih.gov.
11. Lehmann F, Lacombe D, Therasse P, et al. Integration of translational research in the european organization for research and treatment of cancer research (EORTC) clinical trial cooperative group mechanisms. J Transl Med 2003; 1:2. Available at: http://www.translational-medi-cine.com/content/1/1/2.
12. Sonntag KC. Implementations of translational medicine. J Transl Med 2005; 3:33. Available at: http://www.trans-lational-medicine.com/content/3/1/33.
13. Workman P, Kaye SB. Translating basic cancer research into new cancer therapeutics. Trends Mol Med 2002; 4(suppl):S1-S9.
14. Colburn WA. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. J Clin Pharmacol 2000; 40:1419-1427.
15. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sc U S A 1998; 95:6349-6354.
16. Belhocine TZ, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002; 8:2766-2774.
17. Green AM, Steinmetz MD. Monitoring apoptosis in real time. Cancer J 2002; 8:82-92.
18. Boersma HH, Kietselaer BL, Stolk LM, et al. Past, present, and future of annexin A5: from protein discovery to clinical applications. J Nucl Med 2005 ; 46(12):2035-2050 (review).
19. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26:239-257.
20. Hetts SW. To die or not to die: an overview of apoptosis and its role in disease. JAMA 1998; 279:300-307.
21. Israels LG, Israels ED. Apoptosis. Oncologist 1999; 4: 332-339.
22. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by over expression of Bcl-2 and Abl. J Exp Med 1995; 182:1545-1556.
23. Reutelingsperger CPM. Annexins: key regulators of hae-mostasis, thrombosis, and apoptosis. Thromb Haemost 2001; 86:413-419.
24. Huber R, Berendes R, Burger A, et al. Crystal and molecular structure of human annexin V after refinement. Implications for structure, membrane binding and ion channel formation of the annexin family of proteins. J Mol Biol 1992; 223:683-704.
25. Jin M, Smith C, Hsieh HY, et al. Essential role of B-helix calcium binding sites in annexin V-membrane binding. J Biol Chem 2004; 279:40351-40357.
26. Fadok VA, Voelker DR, Campbell PA, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148:2207-2216.
27. Lahorte CM, Vanderheyden JL, Steinmetz N, et al. Apop-tosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging 2004; 31:887-919.
28. Belhocine TZ, Tait JF, Vanderheyden JL, et al. Nuclear medicine in the era of genomics and proteomics: lessons from annexin V. J Proteome Res 2004; 3:345-349.
29. Ohtsuki K, Akashi K, Aoka Y, et al. Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. Eur J Nucl Med 1999; 26:1251-1258.
30. 99mTc-labeled HYNIC-derivat-ized annexin V for human use. Nucl Med Biol 2003; 30:771-778.
31. 99mTc-HYNIC -annexin V, a novel human recombinant annexin V for human application. J Nucl Med 2003; 44:947-952.
32. 99mTc-BTAP-annexin-V in humans. Eur J Nucl Med 2001; 28:1373-1378.
33. 99mTc-annexin V uptake is associated with an increased platinum-based chemotherapy response rate in advanced non-small cell lung cancer. 2004 Annual Meeting, Society of Nuclear Medicine, Philadelphia, U.S.A. (abstr# 1173).
34. 99mTc-HYNIC annexin-V imaging of primary head and neck carcinoma. Nucl Med Commun 2004; 25(3):259-263.
35. Kartachova MS, Valdes Olmos RA, Haas RL, et al. Mapping of treatment-induced apoptosis in normal structures: (99m)Tc-Hynic-rh-annexin V SPECT and CT image fusion. Eur J Nucl Med Mol Imaging 2006; 33(8): 893-899.
36. 99mTc-Hynic-rh-annexin V uptake as an early predictor of response to platinum therapy in advanced non-small cell lung cancer. 2004 Annual Meeting, Society of Nuclear Medicine, Philadelphia, U.S.A. (abstr # 105).
37. 99mTc-Annexin V scintigraphy and tumour response in patients with malignant lymphoma. 2005 Annual Meeting, European Association of Nuclear Medicine, Istanbul, Turkey (abstr # 369).
38. Kartachova M, Haas RL, Olmos RA, et al. In vivo imaging of apoptosis by 99mTc-annexin V scintigraphy: visual analysis in relation to treatment response. Radiother Oncol 2004; 72:333-339.
39. van de Wiele C, Lahorte C, Vermeesch H, et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography. J Clin Oncol 2003; 21:3483-3487.
40. Haas RL, de Jong D, Valdes Olmos RA, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys 2004; 59:782-787.
41. Belhocine T. Radiolabeled recombinant human annexin A5: experimental use and clinical perspectives. Annexins 2004; 1(2):e13-e18.
42. Takei T, Kuge Y, Zhao S, et al. Time course of apoptotic tumor response after a single dose of chemotherapy: comparison with 99mTc-Annexin V uptake and histologic findings in an experimental model. J Nucl Med 2004; 45 (12):2083-2087.
43. Blankenberg FG, Katsikis PD, Tait JF, et al. Imaging of apoptosis (programmed cell death) with 99mTc Annexin V. J Nucl Med 1999; 40:184-191.
44. Kuge Y, Sato M, Zhao S, et al. Feasibility of (99m)Tc- Annexin V for repetitive detection of apoptotic tumor response to chemotherapy: an experimental study using a rat tumor model. J Nucl Med 2004; 45:309-312.
45. 99mTc-Hynic-annexin V after gamma irradiation. 2004 Annual Meeting, Society of Nuclear Medicine, Philadelphia, U.S.A. (abstr # 423).
46. Ke S, Wen X, Wu QP, et al. Imaging taxane-induced tumor apoptotic using PEGylated, 111in-labeled annexin V. J Nucl Med 2004; 45:108-115.
47. 99mTc-annexin V. J Nucl Med 2003; 44:92-97.
48. Bennink RJ, van den Hoff MJ, van Hemert FJ, et al. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med 2004; 45:842-848.
49. 99mTc-annexin V biodistribution in mice with endogenous, virus-induced breast cancer. 2005 Annual Meeting, Society of Nuclear Medicine, Toronto, Canada (abstr # 454).
50. Wang F, Liu M, Zhang CL, et al. Study on tumor cell apoptosis imaging in vivo in mice bearing tumor. 2005 Annual Meeting, Society of Nuclear Medicine, Toronto, Canada (abstr # 453).
51. Kumar V, Wong E, Kumar D, et al. To Evaluate the potential of 99mTc-Hynic-annexin-V in detecting therapy induced apoptosis of thymoma (EL4) tumour in nude mice. 2005 Annual Meeting, European Association of Nuclear Medicine, Istanbul, Turkey (abstr # 368).
52. 99mTc-annexin-V. 2005 Annual Meeting, Society of Nuclear Medicine, Toronto, Canada (abstr # 1270).
53. Yang DJ, Azhdarinia A, Wu P, et al. In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V. Cancer Biother Radiopharm 2001; 16:73-83.
54. Blankenberg FG, Tait J, Strauss HW. Apoptotic cell death: its implications for imaging in the next millennium. Eur J Nucl Med 2000; 27:359-367.
55. Belhocine TZ, Blankenberg FG. 99mTc-Annexin A5 uptake and imaging to monitor chemosensitivity. Methods Mol Med 2005; 111:363-380.
56. Joseph B, Lewensohn R, Zhivothosky B. Role of apoptosis in the response of lung carcinomas to anti-cancer treatment. Ann N Y Acad Sci 2000; 926:204-216 (review).
57. Soini Y, Paakko P, Lehto VP. Histopathological evaluation of apoptosis in cancer. Am J Pathol 1998; 153(4): 1041-1053 (review).
58. Guchelaar HJ, Vermes A, Meerwaldt JH. Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment. Support Care Cancer 1997; 5(4): 281-288 (review).
59. Friesen C, Lubatschofski A, Kotzerke J, et al. Beta irradiation used for systemic radioimmunotherapy induces apop-tosis and activates apoptosis pathways in leukaemia cells. Eur J Nucl Med Mol Imaging 2003; 30(9):1251-1261.
60. Blankenberg F. To scan or not scan, it is a question of timing: technetium-99m-annexin V radionuclide imaging assessment of treatment efficacy after one course of chemotherapy. Clin Cancer Res 2002; 8:2757-2758.
61. Belhocine T, Steinmetz N, Li C, et al. The Imaging of apoptosis with the radiolabeled annexin V: optimal timing for clinical feasibility. Technol Cancer Res Treat 2004; 3: 23-32.
62. Mandl SJ, Mari C, Edinger M, et al. Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome. Mol Imaging 2004; 3:1-8.
63. Lahorte C, Slegers G, Philippe J, et al. Synthesis and in vitro evaluation of 123I-labelled human recombinant annexin V. Bio Eng 2001; 17:51-53.
64. Ito M, Tomiyoshi K, Takahashi N, et al. Development of a new ligand, 11C-labeled annexin V, for PET imaging of apoptosis. Proc SNM 49th Annual Meeting, 2002; No. 1457.
65. Russell J, O'Donoghue JA, Finn R, et al. Iodination of Annexin V for imaging apoptosis. J Nucl Med 2002; 43:671-677.
66. Glaser M, Collingridge DR, Aboagye EO, et al. Iodine-124 labelled Annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl Radiat Isot 2003; 58:55-62.
67. Dekker B, Keen H, Zweit J, et al. Detection of cell death using 124I-Annexin V. Proc SNM 49th Annual Meeting, 2002, No. 256.
68. Keen H, Dekker B, Disley L, et al. Iodine-124 labelled Annexin V for PET imaging of in vivo cell death. Proc SNM 50th Annual Meeting, 2003, No. 586.
69. Watanbe H, Murata Y, Miura M, et al. In-vivo visualization of radiation-induced apoptosis using (125)I-annexin V. Nucl Med Commun 2006; 27(1):81-89.
70. Yang DJ, Azhdarinia A, Wu P, et al. In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V. Cancer Biother Radiopharm 2001; 16(1):73-83.
71. 68Galabelling of annexin-V: comparison to 99mTc-annexin-V and 67Ga-annexin. Proc SNM 50th Annual Meeting, 2003, No. 159.
72. Zijlstra S, Gunawan J, Burchert W. Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET. Appl Radiat Isot 2003; 58:201-207.
73. Vaidayanathan G, Zalutsky MR. Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F] fluorobenzoate. Int J Rad Appl Instrum B 1992; 19:275-281.
74. Boisgard R, Blondel A, Dolle F, et al. A new 18F tracer for apoptosis imaging in tumor bearing mice. Proc SNM 50th Annual Meeting, 2003, No. 157.
75. Mease RC, Weinberg IN, Toretsky JA, et al. Preparation of F-18 labeled Annexin V: a potential PET radiopharmaceut-ical for imaging cell death. Proc SNM 50th Annual Meeting, 2003, No. 1058.
76. Grierson JR, Yagle KJ, Eary JF, et al. Production of [F-18]-fluoroannexin for imaging apoptosis with PET. Bioconjug Chem 2004; 15:373-379.
77. 18F-labelled annexin V: a PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging 2004; 31:469-174.
78. Yagle KJ, Eary JF, Tait JF, et al. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 2005; 46:658-666.
79. 99mTc-BTAP-annexin-V in humans. Eur J Nucl Med 2001; 28:1373-1378.
80. 99mTc-HYNIC -annexin V, a novel human recombinant annexin V for human application. J Nucl Med 2003; 44:947-952.
81. Tait JF, Brown DS, Gibson DF, et al. Development and characterization of Annexin V mutants with endogenous chelation sites for 99mTc. Bioconjug Chem 2005; 11: 918-925.
82. 99mTc-annexin V. J Nucl Med 2005; 46:807-815.
83. Subbarayan M, Hafeli UO, Feyes DK, et al. A simplified method for preparation of 99mTc-annexin V and its biologic evaluation for in vivo imaging of apoptosis after photodynamic therapy. J Nucl Med 2003; 44:650-656.
84. Tait JF, Smith C, Levashova Z, et al. Improved detection of cell death in vivo with annexin v radiolabeled by site-specific methods. J Nucl Med 2006; 47(9):1546-1553.
85. O'Connor MK, Kemp BJ. Single-photon emission computed tomography/computed tomography: basic instrumentation and innovations. Semin Nucl Med 2006; 36(4):258-266.
86. Liu RR, Erwin WD. Automatic estimation of detector radial position for contoured SPECT acquisition using CT images on a SPECT/CT system. Med Phys 2006; 33 (8):2800-2808.
87. Seo Y, Wong KH, Sun M, et al. Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system. J Nucl Med 2005; 46(5): 868-877.
88. Talbot JN, Petegnief Y, De Beco V, et al. Basics of PET and PET/CT imaging: instrumentation and radiopharma-ceuticals for clinical diagnosis. Presse Med 2006; 35(9): 1331-1337 (French).
89. Beyer T, Townsend DW. Putting 'clear' into nuclear medicine: a decade of PET/CT development. Eur J Nucl Med Mol Imaging 2006; 33(8):57-61.
90. Kartachova M, van Zandwijk N, Burgers S, et al. Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J Clin Oncol 2007; 25(18):2534-2539.
91. Rottey S, Loose D, Vakaet L, et al. 99mTc-HYNIC Annexin-V imaging of tumors and its relationship to response to radiotherapy and/or chemotherapy. Q J Nucl Med Mol Imaging 2007; 51(2):182-188.
92. Kartachova MS, Valdes Olmos RA, Haas RL, et al. 99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apopto-sis to predict treatsment outcome. Nucl Med Commun 2008; 29(1):39-44.
93. Seo Y, Mari C, Hasegawa BH. Technological development and advances in single-photon emission computed tomography/computed tomography. Semin Nucl Med 2008; 38 (3):177-198.